Crunching the numbers for RXRX... Refresh in a moment for the full analysis.
RECURSION PHARMACEUTICALS, INC. (RXRX)
Healthcare
weak
$3.28
Updated: 2026-04-12
41
TradeApes Score
reduce
Financial Strength
40
Weak
Operating Trend
55
Mixed
Valuation
40
Weak
Capital Allocation
10
Stressed
Risk
55
Mixed
Key Findings
+
Strong revenue growth — sales up more than 20% year over year
−
Significant dilution — share count up more than 5% year over year
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Create Free Account
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.